Overview

Seebri Neohaler was a prescription drug approved by the U.S. Food and Drug Administration (FDA) for long-term maintenance of airway obstruction in people with chronic obstructive pulmonary disease (COPD). Seebri Neohaler was also known by its drug name, glycopyrrolate. 

Seebri Neohaler was an anticholinergic and a bronchodilator, a drug that dilates the bronchi and bronchioles in the lungs, making it easier to breathe. Seebri Neohaler was believed to work by relaxing smooth muscles in the airways. Seebri Neohaler was considered a long-acting bronchodilator.

How was it taken?

Seebri Neohaler was inhaled orally twice a day. Seebri Neohaler came in the form of powder capsules to be taken using the special Neohaler inhaler.

Side effects

The FDA-approved label for Seebri Neohaler listed common side effects including cold symptoms and upper respiratory tract infections. 

Rare but serious side effects listed for Seebri Neohaler included paradoxical bronchospasm (bronchospasm that happens after using medication) and worsening of glaucoma and urinary retention.

For more details about this treatment, visit:

Seebri — GoodRx